Rezolute, Inc. - Common Stock (NV) (RZLT)

Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024.

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

FDA lifts clinical hold on Rezolute's RZ358 for treating congenital hyperinsulinism, allowing U.S. participants in Phase 3 study. Enrollment expected to start in 2025 with topline data by mid-year.

Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!

Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements in macular edema and a favorable safety profile.

Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning!